A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC

Journal of Infection

Volumn 66, Issue 5, 2013, Pages 464-466

  Jiang, Shibo ^a   Lu, Lu ^a   Du, Lanying ^b   Debnath, Asim K ^b  

^a FUDAN UNIVERSITY   (China)

^b NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRITICAL NEUTRALIZING DOMAIN PROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN; VITRONECTIN;

ALPHA HELIX; BETA SHEET; CORONAVIRUS; CRYSTAL STRUCTURE; DRUG DESIGN; HUMAN BETACORONAVIRUS 2C EMC 2012; LETTER; NONHUMAN; PREDICTION; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DOMAIN; RECEPTOR BINDING; SARS CORONAVIRUS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; X RAY CRYSTALLOGRAPHY;

ANIMALS; CORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS; PANDEMICS; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 84875610424     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.12.003     Document Type: Letter

References (11)

1. Chan J.F.W., Li K.S.M., To K.K.W., Cheng V.C.C., Chen H., Yuen K.Y. Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic?. J Infect 2012, 65:477-489.
2. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D.M.E., Fouchier R.A.M. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367:1814-1820.
3. Anderson L.J., Baric R.S. Emerging human coronaviruses: disease potential and preparedness. N Engl J Med 2012, 367:1850-1852.
4. Butler D. SARS veterans tackle coronavirus. Nature 2012, 490:20.
5. Li W.H., Moore M.J., Vasilieva N., Sui J.H., Wong S.K., Berne M.A., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426:450-454.
6. He Y.X., Zhou Y.S., Liu S.W., Kou Z.H., Li W.H., Farzan M., et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 2004, 324:773-781.
7. He Y., Li J., Du L., Yan X., Hu G., Zhou Y., et al. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Vaccine 2006, 24:5498-5508.
8. Du L., He Y., Zhou Y., Liu S., Zheng B.J., Jiang S. The spike protein of SARS-CoV: a target for vaccine and therapeutic development. Nat Rev Microbiol 2009, 7:226-236.
9. Prabakaran P., Gan J., Feng Y., Zhu Z., Choudhry V., Xiao X., et al. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem 2006, 281:15829-15836.
10. Arnold K., Bordoli L., Kopp J., Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006, 22:195-201.
11. Li F., Li W.H., Farzan M., Harrison S.C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005, 309:1864-1868.